RxDoctor Payments Data

Jacob Lang

Optometrist · Stillwater, MNNPI 1053345835

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Tarsus Pharmaceuticals, Inc. at 26.6% of the total. 2025 is the largest year on record at $89,174, 4.1 times the $21,773 reported in 2019. Among optometrist clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$264,126in general payments, 2019–2025

Across 373 payments — averaging $708.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tarsus Pharmaceuticals, Inc.$70K
  • Sun Pharmaceutical Industries Inc.$51K
  • Dompe US, Inc.$20K
  • Alcon$18K
  • Sparca Ltd$18K
  • Novartis$16K
  • plus $71K from 24 others

What the payments were for

  • Consulting fees$89,43334%
  • Speaking & faculty fees$141,27453%
  • Travel & lodging$25,32210%
  • Food & beverage$8,0383%
  • Gifts$600%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$264,126 in reported general payments places this provider in the 95th percentile of 826 optometrist providers in Minnesota.

See all optometrist providers in Minnesota

Medicare billing

Part B allowed, 2024
$166,047
Medicare patients
426
Services billed
3,199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj20$565,204
XiidraLifitegrast159$227,869
RestasisCyclosporine167$221,604
MieboPerfluorohexyloctane/Pf77$60,407
TyrvayaVarenicline Tartrate48$59,245
XdemvyLotilaner23$43,476
Cyclosporine68$36,585
CequaCyclosporine35$30,330
Fluorometholone413$25,034
Loteprednol Etabonate141$18,308
LumiganBimatoprost26$17,716
EysuvisLoteprednol Etabonate29$14,356
Prednisolone Acetate146$4,480
Latanoprost142$2,273
MoxifloxacinMoxifloxacin Hcl56$1,207

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$19,538$565,20420 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$14,918$288,277236 claims
AbbVieRestasis, Lumigan$13,973$239,319193 claims
Oyster Point Pharma, Inc.Tyrvaya$13,367$59,24548 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$70,233$43,47623 claims
Sun Pharmaceutical Industries Inc.Cequa$51,413$30,33035 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$18$18,308141 claims
Kala Pharmaceuticals, Inc.Eysuvis$1,034$14,35629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 826 optometrist providers in Minnesota.

Other optometrist in Stillwater

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →